Literature DB >> 19801968

Cutting a sentinel lymph node into slices is the optimal first step for examination of sentinel lymph nodes in melanoma patients.

Christina Mitteldorf1, Hans P Bertsch, Antonia Zapf, Christine Neumann, Lutz Kretschmer.   

Abstract

The optimal processing for the pathology of sentinel lymph nodes of patients with melanoma is still a matter of debate. We compared two protocols of sentinel lymph node processing, which were consecutively applied. For the first protocol, the sentinel lymph nodes were cut into 1-2 mm thick slices. From each slice, 12 microtome sections were stained (multiple slices protocol). For the second protocol, which is a modification of the recent European Organisation for Research and Treatment of Cancer protocol, the sentinel lymph nodes were bivalved. Five consecutive series of microtome sections, with gaps of 50 microm between them, were prepared from each cut surface (bivalving protocol). H&E and immunohistochemical staining were integral elements of both protocols. A total of 584 sentinel lymph nodes (1.8+/-0.9 per patient) were examined. The percentages of micrometastases (29 versus 27%) and of capsular naevi (13 versus 15%) detected were very similar for both protocols. As shown by multivariate logistic regression, Breslow thickness (P=0.003) and younger age (P=0.01) correlated with nodal metastasis. The type of histological preparation, ulceration and sex were not significant. The multiple slices protocol produced, on average, 4 paraffin blocks and 46 microtome sections per node. The bivalving protocol constantly produced 2 paraffin blocks and 42 microtome sections. For technical processing, the multiple slices protocol required, on average, 38 min per sentinel lymph node, whereas the bivalving protocol required 55 min. Both protocols yielded excellent detection rates with a similar amount of work being required on the part of the pathologist. Compared with the bivalving protocol, the multiple slices protocol was less labor intensive for the technical staff.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19801968     DOI: 10.1038/modpathol.2009.137

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  5 in total

1.  Guidelines for biomarker testing in metastatic melanoma: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.

Authors:  S Martín-Algarra; M T Fernández-Figueras; J A López-Martín; A Santos-Briz; A Arance; M D Lozano; A Berrocal; J J Ríos-Martín; E Espinosa; J L Rodríguez-Peralto
Journal:  Clin Transl Oncol       Date:  2013-10-16       Impact factor: 3.405

2.  The impact of nodal tumour burden on lymphoscintigraphic imaging in patients with melanomas.

Authors:  Lutz Kretschmer; Hans Peter Bertsch; Pawel Bardzik; Johannes Meller; Simin Hellriegel; Kai-Martin Thoms; Michael Peter Schön; Carsten Oliver Sahlmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-10-15       Impact factor: 9.236

3.  Individualized surgery: gamma-probe-guided lymphadenectomy in patients with clinically enlarged lymph node metastases from melanomas.

Authors:  Lutz Kretschmer; Carsten-Oliver Sahlmann; Pavel Bardzik; Christina Mitteldorf; Hans-Joachim Helms; Johannes Meller; Michael Peter Schön; Hans Peter Bertsch
Journal:  Ann Surg Oncol       Date:  2013-01-12       Impact factor: 5.344

4.  Nodal Basin Recurrence After Sentinel Lymph Node Biopsy for Melanoma: A Retrospective Multicenter Study in 2653 Patients.

Authors:  Lutz Kretschmer; Hans Peter Bertsch; Antonia Zapf; Christina Mitteldorf; Imke Satzger; Kai-Martin Thoms; Bernward Völker; Michael Peter Schön; Ralf Gutzmer; Hans Starz
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

5.  The sentinel node invasion level (SNIL) as a prognostic parameter in melanoma.

Authors:  Lutz Kretschmer; Christina Mitteldorf; Simin Hellriegel; Andreas Leha; Alexander Fichtner; Philipp Ströbel; Michael P Schön; Felix Bremmer
Journal:  Mod Pathol       Date:  2021-06-15       Impact factor: 7.842

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.